EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

IL-33 as a Marker of Poor Early Response in Neuroendocrine Tumor Patients Undergoing Peptide Receptor Radionuclide Therapy

Katarina Vuleta Nedic iD, Nevena Gajovic iD, Ivan Jovanovic iD, Milena Jurisevic, Marina Jovanovic iD, Slobodan Jakovljević, Bojana Popovic, Jelena Djordjevic iD, Vesna Ignjatovic iD, Vladimir Vukomanovic iD

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms26178526 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Katarina Vuleta Nedic und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine and Clinical Oncology, Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia. Hauptthemen laut MEDLINE: Interleukin-33, Neuroendocrine Tumors, Biomarkers, Tumor. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Kragujevac, Faculty of Medical Sciences, (Junior Project N° 12/24)., University of Kragujevac, Faculty of Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite a high disease control rate in the treatment of unresectable or metastatic well-differentiated, somatostatin receptor-positive neuroendocrine tumors (NETs) with peptide receptor radionuclide therapy (PRRT), a certain percentage of patients will experience an unfavorable outcome. Besides clinical, hematological, and biochemical parameters, including widely used inflammatory markers, as well as literature-recognized inflammatory indices, there is a growing need for the identification of novel biomarkers as prognostic factors of therapeutic response. In this prospective single-center study, 51 NET patients treated with PRRT were included and divided into two groups: responders and non-responders in accordance with therapeutic outcome. Cytokine, clinical, and biochemical data were analyzed. Non-responders had significantly higher serum concentrations of IL-33 and IL-4 in comparison to responders, while sST2 was increased in responders. A positive correlation was measured between IL-33 and IL-4, as well as between IL-33 and disease progression. A negative correlation was noted between IL-33 and the neutrophil count %. ROC curve analysis identified values of IL-33 >146.5 pg/mL as a predictor of poor early therapeutic response, and logistic regression confirmed its independent prognostic value. Elevated IL-33 and IL-4 favor the development of a type 2 immune response associated with unfavored therapeutic outcome, while increased sST2 mitigates the IL-33’s effect in responders, contributing to a more favorable response. These findings emphasize IL-33 as an important biomarker of early response in NET patients undergoing PRRT.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Interleukin-33Neuroendocrine TumorsBiomarkers, TumorHumansFemaleMaleMiddle AgedAgedAdultReceptors, SomatostatinOctreotideTreatment OutcomePrognosisProspective StudiesRadioisotopesReceptors, PeptideInterleukin-4ROC Curve

Stichwörter der Autor:innen

IL-33neuroendocrine tumorspeptide receptor radionuclide therapysST2

Substanzen

Interleukin-33IL33 protein, humanBiomarkers, TumorReceptors, SomatostatinOctreotideRadioisotopesReceptors, PeptideInterleukin-4

Autor:innen und Institutionen

  • Department of Nuclear Medicine and Clinical Oncology, Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia.
  • Department for Nuclear Medicine, University Clinical Center Kragujevac, 34000 Kragujevac, Serbia.
  • Center for Molecular Medicine and Stem Cell Research, Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia.
  • Faculty of Medicine, University of East Sarajevo, 73300 Foca, Bosnia and Herzegovina.
  • Department of Clinical Pharmacy, Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia.
  • Department of Otorhinolaryngology, Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia.

ORCID-Profile: Katarina Vuleta Nedic, Nevena Gajovic, Ivan Jovanovic, Marina Jovanovic, Jelena Djordjevic, Vesna Ignjatovic, Vladimir Vukomanovic

Förderung

  • University of Kragujevac, Faculty of Medical Sciences, (Junior Project N° 12/24).
  • University of Kragujevac, Faculty of Medical Sciences

Zitieren

APA

Vuleta Nedic, K., Gajovic, N., Jovanovic, I., Jurisevic, M., Jovanovic, M., Jakovljević, S., Popovic, B., Djordjevic, J., Ignjatovic, V., & Vukomanovic, V. (2025). IL-33 as a Marker of Poor Early Response in Neuroendocrine Tumor Patients Undergoing Peptide Receptor Radionuclide Therapy. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26178526

Vancouver

Vuleta Nedic K, Gajovic N, Jovanovic I, Jurisevic M, Jovanovic M, Jakovljević S, et al. IL-33 as a Marker of Poor Early Response in Neuroendocrine Tumor Patients Undergoing Peptide Receptor Radionuclide Therapy. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26178526

BibTeX
@article{VuletaNedic2025,
  author = {Vuleta Nedic, Katarina and Gajovic, Nevena and Jovanovic, Ivan and Jurisevic, Milena and Jovanovic, Marina and Jakovljević, Slobodan and Popovic, Bojana and Djordjevic, Jelena and Ignjatovic, Vesna and Vukomanovic, Vladimir},
  title = {IL-33 as a Marker of Poor Early Response in Neuroendocrine Tumor Patients Undergoing Peptide Receptor Radionuclide Therapy},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms26178526}
}
Kostenlos starten →